Literature DB >> 12016468

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Ian D Hay1, Geoffrey B Thompson, Clive S Grant, Eric J Bergstralh, Catherine E Dvorak, Colum A Gorman, Megan S Maurer, Bryan McIver, Brian P Mullan, Ann L Oberg, Claudia C Powell, Jon A van Heerden, John R Goellner.   

Abstract

It is uncertain whether more extensive primary surgery and increasing use of radioiodine remnant ablation (RRA) for papillary thyroid carcinoma (PTC) have resulted in improved rates of cause-specific mortality (CSM) and tumor recurrence (TR). Details of the initial presentation, therapy, and outcome of 2444 PTC patients consecutively treated during 1940-1999 were recorded in a computerized database. Patients were followed for more than 43,000 patient-years. The 25-year rates for CSM and TR were 5% and 14%, respectively. Temporal trends were analyzed for six decades. During the six decades, the proportion with initial MACIS (distant Metastasis, patient Age, Completeness of resection, local Invasion, and tumor Size) scores <6 were 77%, 82%, 84%, 86%, 85%, and 82%, respectively (p = 0.06). Lobectomy accounted for 70% of initial procedures during 1940-1949 and 22% during 1950-1959; during 1960-1999 bilateral lobar resection (BLR) accounted for 91% of surgeries (p <0.001). RRA after BLR was performed during 1950-1969 in 3% but increased to 18%, 57%, and 46% in successive decades (p <0.001). The 40-year rates for CSM and TR during 1940-1949 were significantly higher (p = 0.002) than during 1950-1999. During the last 50 years the 10-year CSM and TR rates for the 2286 cases did not significantly change with successive decades. Moreover, the 10-year rates for CSM and TR were not significantly improved during the last five decades of the study, either for the 1917 MACIS <6 patients or the 369 MACIS < 6 patients. Increasing use of RRA has not apparently improved the already excellent outcome, achieved before 1970, in low risk (MACIS <6) PTC patients managed by near-total thyroidectomy and conservative nodal excision.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12016468     DOI: 10.1007/s00268-002-6612-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  172 in total

1.  S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.

Authors:  Martin Nipp; Mareike Elsner; Benjamin Balluff; Stephan Meding; Hakan Sarioglu; Marius Ueffing; Sandra Rauser; Kristian Unger; Heinz Höfler; Axel Walch; Horst Zitzelsberger
Journal:  J Mol Med (Berl)       Date:  2011-09-22       Impact factor: 4.599

2.  Prognostic significance of Tiam1 expression in papillary thyroid carcinoma.

Authors:  Chuen Hsueh; Jen-Der Lin; Chia-Fen Yang; Yu-Sun Chang; Tzu-Chieh Chao; Jui-Hung Sun; I-Chin Wu; Ngan-Ming Tseng; Shir-Hwa Ueng
Journal:  Virchows Arch       Date:  2011-11-11       Impact factor: 4.064

3.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Authors:  Jie Ming; Zeming Liu; Wen Zeng; Yusufu Maimaiti; Yawen Guo; Xiu Nie; Chen Chen; Xiangwang Zhao; Lan Shi; Chunping Liu; Tao Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer.

Authors:  E Robenshtok; R Michael Tuttle
Journal:  Indian J Surg Oncol       Date:  2011-12-20

5.  Malignant thyroid bed mass after total thyroidectomy.

Authors:  Do Sung Park; Jin Seong Cho; Min Ho Park; Young Jae Ryu; Min Jung Hwang; Sun Hyung Shin; Hee Kyung Kim; Hyo Soon Lim; Ji Shin Lee; Jung Han Yoon
Journal:  J Korean Surg Soc       Date:  2013-08-26

6.  Preoperative ultrasound evaluation of laterocervical lymph nodes: timing and experience modify the treatment of patients with differentiated thyroid cancer.

Authors:  Marica Grasso; Alessandro Puzziello; Maurizio De Palma
Journal:  Updates Surg       Date:  2019-01-02

7.  Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients.

Authors:  F Nabhan; K Porter; L Senter; M D Ringel
Journal:  J Endocrinol Invest       Date:  2017-05-16       Impact factor: 4.256

Review 8.  Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.

Authors:  Nicholas S Andresen; John M Buatti; Hamed H Tewfik; Nitin A Pagedar; Carryn M Anderson; John M Watkins
Journal:  Eur Thyroid J       Date:  2017-03-23

9.  Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006.

Authors:  Clive S Grant; John M Stulak; Geoffrey B Thompson; Melanie L Richards; Carl C Reading; Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

10.  Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008.

Authors:  Ian D Hay; Tomas Gonzalez-Losada; Megan S Reinalda; Jennifer A Honetschlager; Melanie L Richards; Geoffrey B Thompson
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.